Skip to main content

Publications

Learn more about the work we do in the Heimberger laboratory through our recent publications.

  1. Kudruk S, Forsyth CM, Dion MZ, Hedlund Orbeck JK, Luo J, Klein RS, Kim AH, Heimberger AB, Mirkin CA, Stegh AH  et al.  Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy.  Proc Natl Acad Sci U S A  2024 Feb 20;121(8):e2306973121. pii:e2306973121
  2. Tripathi S, Najem H, Dussold C, Pacheco S, Miska J, McCortney K, Steffens A, Walshon J, Winkowski D, Cloney M  et al.  Cancer-associated fibroblast-secreted collagen is associated with immune inhibitor receptor LAIR1 in gliomas.  J Clin Invest  2024 Feb 15;134(4). pii:e176613
  3. Hou D, Wan H, Katz JL, Wang S, Castro BA, Vazquez-Cervantes GI, Arrieta VA, Dhiantravan S, Najem H, Rashidi A  et al.  Antigen-presenting B cells promote TCF-1+ PD1- stem-like CD8+ T-cell proliferation in glioblastoma.  Front Immunol  2023;14:1295218. pii:1295218
  4. Tripathi S, Nathan CL, Tate MC, Horbinski CM, Templer JW, Rosenow JM, Sita TL, James CD, Deneen B, Miller SD  et al.  The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions.  JCI Insight  2024 Jan 09;9(1). pii:e174753
  5. Najem H, Arrieta VA, Duffy J, Tripathi S, Zannikou M, Dhiantravan S, Miska J, McCortney K, Steffens A, Walshon J  et al.  Prohibitin Expression in Antigen-Presenting Cells: Implications for Inciting Trigger in CNS IgG4-Related Disease.  Ann Case Rep  2024;9(1). pii:1607
  6. Fares J, Petrosyan E, Kanojia D, Dmello C, Cordero A, Duffy JT, Yeeravalli R, Sahani MH, Zhang P, Rashidi A  et al.  Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.  J Clin Invest  2023 Dec 15;133(24). pii:e161142
  7. McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, Parker S, Baczkowski J, Jennings L, Walshon J  et al.  Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results.  Acta Neuropathol Commun  2023 Nov 02;11(1):175. pii:175
  8. Heimberger AB, Tripathi S, Platanias LC  Targeting Cytokines and Their Pathways for the Treatment of Cancer.  Cancers (Basel)  2023 Oct 30;15(21). pii:5224
  9. Youngblood MW, Erson-Omay Z, Li C, Najem H, Coșkun S, Tyrtova E, Montejo JD, Miyagishima DF, Barak T, Nishimura S  et al.  Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas.  Nat Commun  2023 Oct 07;14(1):6279. pii:6279
  10. Sim HW, Wachsmuth L, Barnes EH, Yip S, Koh ES, Hall M, Jennens R, Ashley DM, Verhaak RG, Heimberger AB  et al.  NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.  Neurooncol Adv  2023;5(1):vdad124. pii:vdad124
  11. Wu SA, Jia DT, Schwartz M, Mulcahy M, Guo K, Tate MC, Sachdev S, Kostelecky N, Escobar DJ, Brat DJ  et al.  HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen.  CNS Oncol  2023 Sep 01;12(3):CNS99. pii:CNS99
  12. Ren X, Manzanares LD, Piccolo EB, Urbanczyk JM, Sullivan DP, Yalom LK, Bui TM, Lantz C, Najem H, Dulai PS  et al.  Macrophage-endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa.  J Clin Invest  2023 Aug 01;133(15). pii:e170733
  13. Sooreshjani M, Tripathi S, Dussold C, Najem H, de Groot J, Lukas RV, Heimberger AB  The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma.  Cancers (Basel)  2023 Jul 23;15(14). pii:3739
  14. Budhiraja S, Najem H, Tripathi S, Wadhawani NR, Horbinski C, McCord M, Lenzen AC, Heimberger AB, DeCuypere M  Immunobiology and Cytokine Modulation of the Pediatric Brain Tumor Microenvironment: A Scoping Review.  Cancers (Basel)  2023 Jul 18;15(14). pii:3655
  15. Choudhury A, Cady MA, Lucas CG, Najem H, Phillips JJ, Palikuqi B, Zakimi N, Joseph T, Birrueta JO, Chen WC  et al.  NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy.  bioRxiv  2023 Jul 11;. pii:2023.07.10.548456
  16. Drumm MR, Wang W, Sears TK, Bell-Burdett K, Javier R, Cotton KY, Webb B, Byrne K, Unruh D, Thirunavu V  et al.  Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.  J Clin Invest  2023 Jun 15;133(12). pii:e168035
  17. Lucas CH, Mirchia K, Seo K, Najem H, Chen W, Zakimi N, Choudhury A, Liu SJ, Phillips J, Magill S  et al.  Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution.  Res Sq  2023 May 15;. pii:rs.3.rs-2921804
  18. Gould A, Gonzales VAA, Dmello CC, Saganty R, Lukas RV, Zhang DY, Heimberger AB, Canney M, Carpentier A, Desseaux C  et al.  Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas.  Adv Oncol  2023 May;3(1):77-86. doi:10.1016/j.yao.2023.01.017
  19. Goethe EA, Heimberger AB, Rao G  Aspirin and immunotherapy: a Faustian bargain?  J Clin Invest  2023 May 01;133(9). pii:e169598
  20. Petrosyan E, Fares J, Fernandez LG, Yeeravalli R, Dmello C, Duffy JT, Zhang P, Lee-Chang C, Miska J, Ahmed AU  et al.  Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment.  Mol Cancer Res  2023 May 01;21(5):389-396. doi:10.1158/1541-7786.MCR-22-0920
  21. Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P  et al.  Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.  Nat Commun  2023 Mar 22;14(1):1566. pii:1566
  22. Burdett KB, Unruh D, Drumm M, Steffens A, Lamano J, Judkins J, Schwartz M, Javier R, Amidei C, Lipp ES  et al.  Determining venous thromboembolism risk in patients with adult-type diffuse glioma.  Blood  2023 Mar 16;141(11):1322-1336. doi:10.1182/blood.2022017858
  23. Youngblood MW, Tran AN, Wang W, An S, Scholtens D, Zhang L, O'Shea K, Pokorny JL, Magill ST, Sachdev S  et al.  Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.  Neuro Oncol  2023 Mar 14;25(3):508-519. doi:10.1093/neuonc/noac206
  24. Pang L, Dunterman M, Xuan W, Gonzalez A, Lin Y, Hsu WH, Khan F, Hagan RS, Muller WA, Heimberger AB  et al.  Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma.  Cell Rep  2023 Feb 28;42(2):112127. doi:10.1016/j.celrep.2023.112127
  25. Khan AB, Lee S, Harmanci AS, Patel R, Latha K, Yang Y, Marisetty A, Lee HK, Heimberger AB, Fuller GN  et al.  CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma.  Int J Cancer  2023 Feb 15;152(4):713-724. doi:10.1002/ijc.34329
  26. Zhao Q, Hu J, Kong L, Jiang S, Tian X, Wang J, Hashizume R, Jia Z, Fowlkes NW, Yan J  et al.  FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells.  Nat Commun  2023 Feb 10;14(1):735. pii:735
  27. Liang J, Fang D, Gumin J, Najem H, Sooreshjani M, Song R, Sabbagh A, Kong LY, Duffy J, Balyasnikova IV  et al.  A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin.  Cancers (Basel)  2023 Feb 08;15(4). pii:1085
  28. Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM  Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.  J Clin Invest  2023 Jan 17;133(2). pii:e163447
  29. Adekanmbi A, Youngblood MW, Karras CL, Oyetunji EA, Kalapurakal J, Horbinski CM, Najem H, Hill VB, Chandler JP, Heimberger AB  et al.  Clinical Management of Supratentorial Non-Skull Base Meningiomas.  Cancers (Basel)  2022 Nov 29;14(23). pii:5887
  30. McCord M, Bartom E, Burdett K, Baran A, Eckerdt FD, Balyasnikova IV, McCortney K, Sears T, Cheng SY, Sarkaria JN  et al.  Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts.  Cancers (Basel)  2022 Nov 09;14(22). pii:5494
  31. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT  et al.  Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.  Ann Oncol  2022 Nov;33(11):1204-1206. doi:10.1016/j.annonc.2022.07.009
  32. Pang L, Khan F, Heimberger AB, Chen P  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.  Trends Cancer  2022 Oct;8(10):839-854. pii:S2405-8033(22)00097-8
  33. Tripathi S, Najem H, Mahajan AS, Zhang P, Low JT, Stegh AH, Curran MA, Ashley DM, James CD, Heimberger AB  cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.  F1000Res  2022;11:1010. pii:1010
  34. Fischietti M, Eckerdt F, Perez RE, Guillen Magaña JN, Mazewski C, Ho S, Gonzalez C, Streich LD, Beauchamp EM, Heimberger AB  et al.  SLFN11 negatively regulates non-canonical NFkB signaling to promote glioblastoma progression.  Cancer Res Commun  2022 Sep;2(9):966-978. doi:10.1158/2767-9764.crc-22-0192
  35. Cao TQ, Wainwright DA, Lee-Chang C, Miska J, Sonabend AM, Heimberger AB, Lukas RV  Next Steps for Immunotherapy in Glioblastoma.  Cancers (Basel)  2022 Aug 20;14(16). pii:4023
  36. Zhu M, Li S, Kuang Y, Hill VB, Heimberger AB, Zhai L, Zhai S  Artificial intelligence in the radiomic analysis of glioblastomas: A review, taxonomy, and perspective.  Front Oncol  2022;12:924245. pii:924245
  37. Zamler DB, Shingu T, Kahn LM, Huntoon K, Kassab C, Ott M, Tomczak K, Liu J, Li Y, Lai I  et al.  Immune landscape of a genetically engineered murine model of glioma compared with human glioma.  JCI Insight  2022 Jun 22;7(12). pii:e148990
  38. Larkin CJ, Arrieta VA, Najem H, Li G, Zhang P, Miska J, Chen P, James CD, Sonabend AM, Heimberger AB  Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era.  Front Immunol  2022;13:907605. pii:907605
  39. Xuan W, Hsu WH, Khan F, Dunterman M, Pang L, Wainwright DA, Ahmed AU, Heimberger AB, Lesniak MS, Chen P  Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma.  Cancer Immunol Res  2022 Jun 03;10(6):770-784. doi:10.1158/2326-6066.CIR-21-0559
  40. Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK  et al.  A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.  CNS Oncol  2022 Jun 01;11(2):CNS87. pii:CNS87
  41. Zhang S, Black RG, Kohli K, Hayes BJ, Miller C, Koehne A, Schroeder BA, Abrams K, Schulte BC, Alexiev BA  et al.  B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.  Mol Cancer Ther  2022 Jun 01;21(6):999-1009. doi:10.1158/1535-7163.MCT-21-0726
  42. Low JT, Chandramohan V, Bowie ML, Brown MC, Waitkus MS, Briley A, Stevenson K, Fuller R, Reitman ZJ, Muscat AM  et al.  Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition.  Cancer Cell  2022 May 09;40(5):439-440. doi:10.1016/j.ccell.2022.04.009
  43. Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A  et al.  Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression.  JCI Insight  2022 May 09;7(9). pii:e157612
  44. Wei J, Song R, Sabbagh A, Marisetty A, Shukla N, Fang D, Najem H, Ott M, Long J, Zhai L  et al.  Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system.  Oncoimmunology  2022;11(1):2062827. pii:2062827
  45. Vogelbaum MA, Li G, Heimberger AB, Lang FF, Fueyo J, Gomez-Manzano C, Sanai N  A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.  Am Soc Clin Oncol Educ Book  2022 Apr;42:1-8. doi:10.1200/EDBK_349175
  46. Mahajan AS, Stegh AH  Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside.  Cancers (Basel)  2022 Mar 23;14(7). pii:1615
  47. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C  et al.  Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.  Nat Cancer  2022 Mar;3(3):373. doi:10.1038/s43018-022-00343-8
  48. Larkin CJ, Jennings LJ, Heimberger AB, Horbinski C  Next-Generation Sequencing of a Glioblastoma with True Epithelial Differentiation.  J Neuropathol Exp Neurol  2022 Feb 24;81(3):239-241. doi:10.1093/jnen/nlab114
  49. Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM  et al.  Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.  Clin Cancer Res  2022 Feb 15;28(4):585-593. doi:10.1158/1078-0432.CCR-21-2681
  50. Khasraw M, Fujita Y, Lee-Chang C, Balyasnikova IV, Najem H, Heimberger AB  New Approaches to Glioblastoma.  Annu Rev Med  2022 Jan 27;73:279-292. doi:10.1146/annurev-med-042420-102102

Follow Heimberger Lab on